Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
NCT05997615
This study is recruiting at 10 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
There are many treatment options for men with various stages of prostate cancer. Some treatments work well for a while but can cause medical problems in some men. Also, the cancer may come back after treatment. This is an early development study of VIR-5500 in men with prostate cancer. In this study, VIR-5500 will be given to people for the first time. VIR-5500 will either be given by itself or given together with one or more standard cancer treatments: enzalutamide, darolutamide and docetaxel.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Hormone-refractory Prostate Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- Astellas Pharma Global Development, Inc.
- Last updated on ClinicalTrials.gov
- October 27, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 6
- Duarte Cancer Center · Duarte, CA
- Lennar Foundation Cancer Center · Irvine, CA
- University of California Irvine · Irvine, CA
- UCI Health Chao Family Comprehensive Cancer Center · Orange, CA
- Stanford University · Palo Alto, CA
- University of California · San Francisco, CA
Illinois · 1
- Chicago Cancer Center · Zion, IL
Texas · 1
- MD Anderson Cancer Center · Houston, TX
Virginia · 1
- NEXT Virginia · Fairfax, VA
Washington · 1
- Fred Hutchinson Cancer Research Center · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.